In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015 to 2017.

Icon for Elsevier Science Related Articles

In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015 to 2017.

Int J Antimicrob Agents. 2020 Jun 06;:106045

Authors: Stone GG, Seifert H, Nord CE

Abstract
BACKGROUND: Between 2015 and 2017, 21,850 Enterobacterales isolates and 6,156 Pseudomonas aeruginosa isolates were collected by 77 centers in 18 European countries as part of the INFORM study (which was included into the Antimicrobial Testing Leadership and Surveillance [ATLAS] study in 2018).
METHODS: A central reference laboratory performed antimicrobial susceptibility testing using broth microdilution panels according to CLSI guidelines. The presence of β-lactamases was confirmed using multiplex PCR assays.
RESULTS: Among Enterobacterales isolates, highest rates of susceptibility were to ceftazidime-avibactam (99.0%; MIC90 0.5 mg/L), meropenem (96.3%), amikacin (95.2%%), and imipenem (92.8%). All Enterobacterales organisms were highly susceptible to colistin (≥94.6%), apart from Proteus mirabilis, which is intrinsically resistant to colistin. Susceptibility rates among ceftazidime-resistant isolates were 95.7% for ceftazidime-avibactam and 87.9% for colistin, and 78.5% and 71.1% respectively among carbapenemase-positive isolates. Colistin was the only agent with activity against metallo-β-lactamases (100% susceptibility) among Enterobacterales and P. aeruginosa isolates. Overall susceptibility rates among P. aeruginosa were highest to colistin (99.5%) and ceftazidime-avibactam (92.3%), and were similar to ceftazidime-resistant isolates for colistin (98.9%) and reduced to 66.2% for ceftazidime-avibactam. Susceptibility rates among multidrug-resistant P. aeruginosa isolates were 98.9% to colistin, and 71.7% to ceftazidime-avibactam.
CONCLUSIONS: Clinical isolates of Enterobacterales and P. aeruginosa collected from Europe, between 2015 and 2017, were highly susceptible to ceftazidime-avibactam, suggesting it is a useful alternative agent for patients whose treatment options may be limited. Persistent antimicrobial resistance requires continued surveillance and monitoring.

PMID: 32522673 [PubMed - as supplied by publisher]